Aug 08, 2025 • Motley Fool
NEUTRAL
Cg Oncology ( CGON ) Q2 Loss Widens 93%
Cg Oncology ( NASDAQ:CGON ) , a clinical-stage biotechnology company focused on developing therapies for bladder cancer, reported its second quarter fiscal 2025 earnings on August 8, 2025. The company disclosed a net loss that was more than double that of the same quarter in 2024.
Aug 08, 2025 • GlobeNewswire
NEUTRAL
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting -
Aug 06, 2025 • Zacks Commentary
NEUTRAL
Arbutus Biopharma ( ABUS ) Beats Q2 Earnings and Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 15, 2025 • Benzinga
NEUTRAL
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Jul 15, 2025 • GlobeNewswire
NEUTRAL
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) , a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( TIL ) therapies for patients with cancer, today announced ...
May 22, 2025 • Zacks Commentary
NEUTRAL
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.